These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32056743)

  • 1. Phosphodiesterase-5 inhibitors: Shedding new light on the darkness of depression?
    Duarte-Silva E; Filho AJMC; Barichello T; Quevedo J; Macedo D; Peixoto C
    J Affect Disord; 2020 Mar; 264():138-149. PubMed ID: 32056743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
    Yafi FA; Sharlip ID; Becher EF
    Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Genetic Polymorphism on the Response to PDE5 Inhibitors in Patients With Erectile Dysfunction: A Systematic Review and a Critical Appraisal.
    Mostafa T; Hassan A; Alghobary MF; Abdelrahman SH
    Sex Med Rev; 2020 Oct; 8(4):573-585. PubMed ID: 32636154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors.
    Hong JH; Kwon YS; Kim IY
    Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):183-192. PubMed ID: 27690667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral phosphodiesterase type 5 inhibitors and male reproductive potential: an overview.
    Mostafa T; Alghobary M; Hanafy NS; Abosief A
    Sex Med Rev; 2023 Jun; 11(3):240-252. PubMed ID: 36990971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Placebo Responses Among Men With Erectile Dysfunction Enrolled in Phosphodiesterase 5 Inhibitor Trials: A Systematic Review and Meta-analysis.
    Stridh A; Pontén M; Arver S; Kirsch I; Abé C; Jensen KB
    JAMA Netw Open; 2020 Mar; 3(3):e201423. PubMed ID: 32196105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple PDE5Is use as a marker of decreased overall men's health: A real-life study.
    Oreggia D; Ventimiglia E; Capogrosso P; Boeri L; Cazzaniga W; Pederzoli F; Chierigo F; Dehò F; Montorsi F; Salonia A
    PLoS One; 2018; 13(8):e0201601. PubMed ID: 30096166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-Intensity Extracorporeal Shockwave Therapy Can Improve Erectile Function in Patients Who Failed to Respond to Phosphodiesterase Type 5 Inhibitors.
    Tsai CC; Wang CJ; Lee YC; Kuo YT; Lin HH; Li CC; Wu WJ; Liu CC
    Am J Mens Health; 2017 Nov; 11(6):1781-1790. PubMed ID: 28884638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Ventimiglia E; Capogrosso P; Montorsi F; Salonia A
    Expert Opin Drug Saf; 2016; 15(2):141-52. PubMed ID: 26752541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avanafil - a further step to tailoring patient needs and expectations.
    Boeri L; Capogrosso P; Ventimiglia E; Serino A; La Croce G; Russo A; Damiano R; Montorsi F; Salonia A
    Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1171-81. PubMed ID: 27232892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac uses of phosphodiesterase-5 inhibitors.
    Schwartz BG; Levine LA; Comstock G; Stecher VJ; Kloner RA
    J Am Coll Cardiol; 2012 Jan; 59(1):9-15. PubMed ID: 22192662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on preoperative erectile function.
    Basal S; Wambi C; Acikel C; Gupta M; Badani K
    BJU Int; 2013 Apr; 111(4):658-65. PubMed ID: 23186312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis.
    Tsertsvadze A; Fink HA; Yazdi F; MacDonald R; Bella AJ; Ansari MT; Garritty C; Soares-Weiser K; Daniel R; Sampson M; Fox S; Moher D; Wilt TJ
    Ann Intern Med; 2009 Nov; 151(9):650-61. PubMed ID: 19884626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors.
    Jannini EA; DeRogatis LR; Chung E; Brock GB
    J Sex Med; 2012 Jan; 9(1):26-33. PubMed ID: 22221307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Meta-Analysis of Long- Versus Short-Acting Phosphodiesterase 5 Inhibitors: Comparing Combination Use With α-Blockers and α-Blocker Monotherapy for Lower Urinary Tract Symptoms and Erectile Dysfunction.
    Choi H; Kim HJ; Bae JH; Kim JH; Moon du G; Cheon J; Yeo JK
    Int Neurourol J; 2015 Dec; 19(4):237-45. PubMed ID: 26739178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review and meta-analysis of phosphodiesterase type 5 inhibitors for the treatment of female sexual dysfunction.
    Gao L; Yang L; Qian S; Li T; Han P; Yuan J
    Int J Gynaecol Obstet; 2016 May; 133(2):139-45. PubMed ID: 26797204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical treatment of erectile dysfunction: too many medical prescriptions?
    Capogrosso P; Ventimiglia E; Oreggia D; Salonia A; Montorsi F
    Urologia; 2017 Aug; 84(3):121-129. PubMed ID: 28708203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of the prevalence and patterns of phosphodiesterase type 5 inhibitor use among sexually active Egyptian males: A National Cross-sectional Survey.
    Attia AA; Abdel-Hameed AKS; Amer MAEM; Mamdouh H; GamalEl Din SF; El-Moslemany HEGM
    Andrologia; 2019 Oct; 51(9):e13364. PubMed ID: 31304987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADMET considerations for phosphodiesterase-5 inhibitors.
    Rezvanfar MA; Rahimi HR; Abdollahi M
    Expert Opin Drug Metab Toxicol; 2012 Oct; 8(10):1231-45. PubMed ID: 22769968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the efficacy and safety of mirodenafil in the management of erectile dysfunction.
    Cho MC; Paick JS
    Ther Adv Urol; 2016 Apr; 8(2):100-17. PubMed ID: 27034723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.